154. Development of a concussion drug with Michael Wyand

Michael Wyand is CEO of Oxeia Biopharmaceuticals, a clinical-stage biotech company developing new, innovative therapeutics for mild traumatic brain injury (mTBI), known as concussion, and related neuro-metabolic dysfunction. The company has a drug, OXE103, that successfully completed a pilot Phase 2a clinical trial in the fall of 2022. The study showed robust treatment effect across study endpoints. The endpoints were a reduction in symptom burden and improvement in quality of life. The OXE103 responder rate was 85% vs. a baseline of 33%. Michael earned his post-Doc in Comparative Pathology at Harvard Medical School and a PhD in Comparative Pathology at the University of Connecticut. He has held leadership positions at a number of companies such as Epirus Biopharmaceuticals, Percivia and BioAssets Development Corporation. Michael uses his medical background and business experience with hope to bring relief to the millions of Americans who each year suffer from head injury. Find Michael at: https://www.oxeiabiopharma.com/Email: [email protected]            [email protected]: https://www.linkedin.com/company/oxeia-biopharmaceuticals-inc/X: @oxeia  Find more about Brain Wellness at: https://brainwellnesssolutions.com/Support the show with Buy me a Coffee: https://www.buymeacoffee.com/brainwellnessnp